Annexon ANNX 深 沪
等待开盘 09-02 09:30:00 美东时间
4.89
-0.050
-1.01%
华盛通- 最 高5.00
- 今 开4.96
- 成交量 147.26万股
- 最 低 4.85
- 昨 收 4.94
- 总市值 9.27亿
- 52周最高 7.18
- 市盈率 静 --
- 换手率 0.78%
- 52周最低 2.32
- 委 比 30.46%
- 总股本 1.90亿
- 历史最高 38.01
- 量 比 0.60
- 振 幅 3.04%
- 历史最低 1.285
- 每 手 1
- 风险率 1.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 美银上调微软目标价从500美元升至600美元；BlossomHill获小摩等多家大行首予买入评级
今日重点评级关注：BTIG：维持Kazia Therapeutics"买入"评级，目标价从34美元升至40美元；摩根大通：维持Annexon"超配"评级，目标价从10美元升至14美元
今天 14:07
JP Morgan Maintains Overweight on Annexon, Raises Price Target to $14
JP Morgan analyst Anupam Rama maintains Annexon (NASDAQ:ANNX) with a Overweight and raises the price target from $10 to $14.
今天 02:34
Annexon (ANNX) 2026年第二季度业绩电话会议：ARCHER II试验扩大，BLA申请按计划推进
Annexon的2026财年第二季度业绩电话会议涵盖了ARCHER II研究新的第24个月终点、FORWARD研究的初步数据，以及计划于第四季度提交的tanruprubart BLA（生物制品许可申请）。
08-17 08:01
Citizens Upgrades Annexon to Market Perform
Citizens analyst Jonathan Wolleben upgrades Annexon (NASDAQ:ANNX) from Market Underperform to Market Perform.
08-13 21:48
Annexon Biosciences highlights pivotal 2026 clinical progress
Annexon Biosciences ( ($ANNX) ) has provided an announcement. On August 12, 202...
08-12 18:58
Annexon Q2 EPS $(0.28) Misses $(0.24) Estimate
Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.24) by 16.67 percent. This is a 17.65 percent increase over losses of $(0.34) per share from the same period last year.
08-12 18:14
Annexon Adds Month 24 Dual Primary Endpoint To Complement Current Month 15 Primary Endpoint In Phase 3 ARCHER II Trial And Launches OLE Study Of Vonaprument For Treatment Of Dry AMD With Geographic Atrophy
Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced the addition of a Month 24 dual primary endpoint to complement the curre...
08-12 18:03
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
Annexon announced the addition of a Month 24 dual primary endpoint to its Phase 3 ARCHER II trial for vonaprument, targeting dry AMD with geographic atrophy (GA). This complements the existing Month 15 endpoint, enhancing the trial's ability to demonstrate efficacy. The trial's strong execution and statistical power support this expansion. An open-label extension study will evaluate vonaprument's long-term safety and benefit. Vonaprument has rece...
08-12 10:00
Annexon Biosciences Adds Retinal Expert to Board
An announcement from Annexon Biosciences ( ($ANNX) ) is now available. On Augus...
08-11 06:24
Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors
<p>Annexon, Inc. announced the appointment of Mark S. Blumenkranz, M.D., M.M.S., to its board of directors, bringing over four decades of expertise in retinal disease. The company also announced the departure of Muneer Satter after 11 years of service. Dr. Blumenkranz, a renowned retinal surgeon and entrepreneur, will contribute to advancing Annexon's late-stage clinical programs, particularly vonaprument for geographic atrophy. The company highl...
08-10 20:05
